Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

346 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ. Sarich TC, et al. J Thromb Haemost. 2003 May;1(5):999-1004. doi: 10.1046/j.1538-7836.2003.00201.x. J Thromb Haemost. 2003. PMID: 12871368 Clinical Trial.
Antithrombotic effects were assessed as changes in total thrombus area (TTA) and total fibrin area (TFA) from baseline, using the Badimon perfusion chamber model at baseline and 2 h and 5 h after drug administration. ...
Antithrombotic effects were assessed as changes in total thrombus area (TTA) and total fibrin area (TFA) from baseline, using the Badimon
Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist.
Osende JI, Shimbo D, Fuster V, Dubar M, Badimon JJ. Osende JI, et al. J Thromb Haemost. 2004 Mar;2(3):492-8. doi: 10.1111/j.1538-7933.2004.00639.x. J Thromb Haemost. 2004. PMID: 15009468
The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrin(ogen) deposition. ...
The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic …
Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay.
Bogdanov VY, Cimmino G, Tardos JG, Tunstead JR, Badimon JJ. Bogdanov VY, et al. J Thromb Haemost. 2009 May;7(5):894-7. doi: 10.1111/j.1538-7836.2009.03315.x. Epub 2009 Feb 12. J Thromb Haemost. 2009. PMID: 19220730 No abstract available.
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Natarajan A, Marshall SM, Worthley SG, Badimon JJ, Zaman AG. Natarajan A, et al. J Thromb Haemost. 2008 Dec;6(12):2210-3. doi: 10.1111/j.1538-7836.2008.03176.x. Epub 2008 Oct 1. J Thromb Haemost. 2008. PMID: 18983525 No abstract available.
A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall--studies in a porcine model.
Badimon L, Martínez-González J, Royo T, Lassila R, Badimon JJ. Badimon L, et al. Thromb Haemost. 1999 Dec;82(6):1736-42. Thromb Haemost. 1999. PMID: 10613663
In vitro and ex vivo perfusion experiments were performed using the Badimon chamber at high shear rate conditions (1690 s(-1)). ...
In vitro and ex vivo perfusion experiments were performed using the Badimon chamber at high shear rate conditions (1690 s(-1)). ...
Thrombin in arterial thrombosis.
Badimon L, Meyer BJ, Badimon JJ. Badimon L, et al. Haemostasis. 1994 Mar-Apr;24(2):69-80. doi: 10.1159/000217087. Haemostasis. 1994. PMID: 7959365 Review.
Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.
Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS. Lev EI, et al. Thromb Haemost. 2006 Mar;95(3):441-6. doi: 10.1160/TH05-10-0700. Thromb Haemost. 2006. PMID: 16525571 Clinical Trial.
Blood thrombogenicity was assessed using the Badimon ex vivo perfusion chamber. Each patient underwent two perfusion studies - at baseline (on aspirin and clopidogrel) and 15-20 minutes following PCI. ...
Blood thrombogenicity was assessed using the Badimon ex vivo perfusion chamber. Each patient underwent two perfusion studies - at bas …
346 results
Jump to page
Feedback